NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
5.76
+0.1 (+1.77%)
The current stock price of MNKD is 5.76 USD. In the past month the price decreased by -3.19%. In the past year, price increased by 62.25%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 414 full-time employees. The company went IPO on 2004-07-28. The company is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
MANNKIND CORP
1 Casper Street
Danbury CONNECTICUT 91362 US
CEO: Michael E. Castagna
Employees: 414
Company Website: https://mannkindcorp.com/
Investor Relations: https://investors.mannkindcorp.com
Phone: 18186615000
The current stock price of MNKD is 5.76 USD. The price increased by 1.77% in the last trading session.
The exchange symbol of MANNKIND CORP is MNKD and it is listed on the Nasdaq exchange.
MNKD stock is listed on the Nasdaq exchange.
11 analysts have analysed MNKD and the average price target is 10.2 USD. This implies a price increase of 77.08% is expected in the next year compared to the current price of 5.76. Check the MANNKIND CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MANNKIND CORP (MNKD) has a market capitalization of 1.59B USD. This makes MNKD a Small Cap stock.
MANNKIND CORP (MNKD) currently has 414 employees.
MANNKIND CORP (MNKD) has a support level at 5.44 and a resistance level at 5.77. Check the full technical report for a detailed analysis of MNKD support and resistance levels.
The Revenue of MANNKIND CORP (MNKD) is expected to grow by 45.04% in the next year. Check the estimates tab for more information on the MNKD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MNKD does not pay a dividend.
MANNKIND CORP (MNKD) will report earnings on 2025-02-26, after the market close.
The PE ratio for MANNKIND CORP (MNKD) is 115.2. This is based on the reported non-GAAP earnings per share of 0.05 and the current share price of 5.76 USD. Check the full fundamental report for a full analysis of the valuation metrics for MNKD.
The outstanding short interest for MANNKIND CORP (MNKD) is 10.08% of its float. Check the ownership tab for more information on the MNKD short interest.
ChartMill assigns a technical rating of 4 / 10 to MNKD. When comparing the yearly performance of all stocks, MNKD is one of the better performing stocks in the market, outperforming 87.46% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to MNKD. MNKD has an average financial health and profitability rating.
Over the last trailing twelve months MNKD reported a non-GAAP Earnings per Share(EPS) of 0.05. The EPS increased by 141.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 8.07% | ||
ROA | 4.65% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 85% to MNKD. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 320.32% and a revenue growth 45.04% for MNKD